Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6082 ARTÍCULOS , VIENDO DEL 3646 AL 3660

One world, one goal: Advocacy and policy for a unified Parkinson's response

Fothergill-Misbah N.

J Parkinsons Dis. 2026 May 7:1877718X261448383. doi: 10.1177/1877718X261448383. Online ahead of print.

Clinical utility of evoked potentials for programming subthalamic deep brain stimulation in Parkinsons disease

Hale B, Latorre A, Rocchi L, Rothwell J, Limousin P.

NPJ Parkinsons Dis. 2026 Jan 23;12(1):54. doi: 10.1038/s41531-026-01274-2.

Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease

Safarpour D, Brooks A, Smiley A, Katzka DA, Shprecher DR, Greene JG, Pahwa R, Troche MS, Kriegel Z, Peron EP, Bryant A, Fasano A, Ochoa M, Ramirez-Zamora A, Acevedo M, Blackwell GM, Pfeiffer RF, Parkman HP, Quigley EM, Cloud L.

J Parkinsons Dis. 2026 Feb;16(1):16-35. doi: 10.1177/1877718X251410503. Epub 2026 Jan 5.

Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis

Solla P, Masala C, Martinez G, Galiero R, Floris V, Ogana E, Canu V, Loy F, Ercoli T.

Brain Sci. 2026 May 21;16(5):545. doi: 10.3390/brainsci16050545.

Microglia heterogeneity and therapeutic strategies in Parkinson's disease

Tian J, Liu X, Wang Z, Shi X, Dai C, Yang L.

Front Immunol. 2026 Feb 5;17:1739341. doi: 10.3389/fimmu.2026.1739341. eCollection 2026.

Ferritin in ferroptosis: Implications for neurodegenerative diseases (Review)

Chen W, Tian H, Wei R, Chen X, Jia Y.

Int J Mol Med. 2026 May;57(5):119. doi: 10.3892/ijmm.2026.5790. Epub 2026 Mar 13.

Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies

Dzamko N.

CNS Drugs. 2026 Apr;40(4):509-522. doi: 10.1007/s40263-026-01275-y. Epub 2026 Feb 17.

The Ubiquitin-proteasome system in neuroinflammation and neurodegeneration: Molecular insights and therapeutic avenues

Guo Y, Wang N, Tao Z, Huang X, Yu W, Zeng J, Liu X, Chen S, Hua F, Wang X.

Int Immunopharmacol. 2026 Jun 15;179:116599. doi: 10.1016/j.intimp.2026.116599. Epub 2026 Apr 11.

The Multifaceted Roles of Eukaryotic Elongation Factor 1-Alpha-2 in Neurodevelopmental and Neurodegenerative Disorders

Khwanraj K, Prommahom A, Dharmasaroja P.

ScientificWorldJournal. 2026;2026(1):e4373377. doi: 10.1155/tswj/4373377.

Modeling human neurodegenerative disorders in Drosophila: strategies and translational opportunities

Mohamed SA, Badr OA.

Mol Biol Rep. 2026 May 12;53(1):745. doi: 10.1007/s11033-026-11844-5.

α-synuclein PET imaging: early human evidence and the path toward clinical proof-of-concept

Filippi L, Urbano N.

Expert Rev Mol Diagn. 2026 Jun;26(6):453-460. doi: 10.1080/14737159.2026.2675385. Epub 2026 May 17.

How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein Disease

Simuni T, Coffey CS, Kopil CM, Allen-Savietta C, Wendelberger B, Crawford A, Schneider RB, Siderowf A, Kieburtz K, Tanner CM, Tropea TF, Whalen H, Ramia L, Kamp C, Reyes C, Fabrizio K, Willson T, Merriam E, Kuhl MM, Chowdhury S, Marek K; Parkinson's Progression Markers Initiative.

Ann Neurol. 2026 Oct;100 Suppl 38:S97-S105. doi: 10.1002/ana.78250. Epub 2026 May 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias